UK small-cap RNS · 29 Sep 2026

Liberation's strategic review found no acceptable offers, expected funding was not received and a c.$25m gap remains. The Richmond plant misses its Q4 2026 completion target, and funding is only targeted for H1 2027.

Wider loss of £1.440m, driven by an £849k share-based charge, and cash of only £0.051m at 30 June. Azteca has since reached hot commissioning, and a £2.25m raise followed the period end.

Scheme Document published for the recommended 250p final cash offer; the board unanimously backs it, and shareholder meetings on 30 Oct 2026 move the deal toward completion in Q4 2026 or Q1 2027.

Late 2026 accounts breach AIM Rule 19, so the shares are suspended from 1 October 2026. This repeats the earlier suspension and hampers the cash shell's six-month reverse takeover search.

RHIM says it is in advanced talks with the Vesuvius board on a possible recommended cash-and-share offer at 549p, a c.47% premium. The board is no longer simply rejecting.

The SPA is signed, but nothing has completed. The US$33m reverse takeover still needs funding, a prospectus and shareholder approval. The target is pre-revenue and loss-making, and funders are only 'at varying stages'.

SEED Innovations Limited (AIM: SEED), the investing company focused on early-stage physical AI and robotics, is pleased to announce a retail offer via the Winterflood Retail Access Platform (“WRAP”) to raise approximately £150,000 (the “Retail Offer”) through …

Continuing revenue grew 16.0% proforma on volume and adjusted EBITDA rose to £7.9m, but EBITDA margin fell to 15.7% and continuing diluted EPS was a 2.98p loss.

Near-term H2 volumes slower than anticipated, with some revenue pushed into FY27 by Middle East deferrals and a UK supplier outage. H2 EBITDA only similar to H2 FY25, trimming the 'material improvement' guided in June.

Loyalty membership is growing, with Burrito Society above 385,000 members and member revenue up about 50%. Growing delivery and in-store demand supports the UK sales momentum.

GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease (“CVD”) and risk of ovarian cancer announces its unaudited interim results for the six months ended 30 June 2026.

Year-end backlog was £83.5m, below last year's £93.4m. The record award then lifted it to about £115m by 31 July, giving revenue visibility into FY27 after the weak H1 bookings.

Interim results show net assets up to £87m after the March raise and a wider loss of £4.6m. The 4 Sep fatal incident and development suspension overshadow the funded construction progress.

H1 revenue rose 29.1% and profit before tax 70.1% after a weak 2025, and full-year results are expected in line with market expectations, so the recovery is on track.

Unaudited Interim Results for the six months ended 30 June 2026

Fundraising to Advance Physical AI & Robotics Strategy

H1 revenue and adjusted EBITDA fell year on year as Research normalised, and full-year guidance rests on a stronger H2 from NIOX PRO rollout, Japan pricing and the deferred Clinical demand.

Guidance moves from 'in line' at the May interims to FY2026 'ahead of market expectations' (consensus £37.2m adjusted operating profit). Stronger collectables demand and a record World Cup contribution drove the beat.

Interim profit before tax of £6.248m (H1 2025: £0.151m) follows the Zenit part-sale, while cash of c.£17.3m (£5.4m at start of year) funds the Dokwe DFS without new equity.

The Capital Markets Day sets out unit growth targets and KPIs under the reorganised four-unit structure, but the group 5–8% net revenue growth ambition and £30m a year buyback are unchanged, so nothing new for the group.